Advancing PARG Inhibition: From Preclinical Rationale to Early Clinical Development

• See how FoRx Therapeutics is progressing PARG inhibition with FORX-428 to differentiate from other DDR targets

• Positioning FORX-428 as a best-in-class candidate for PARG inhibition in cancer treatment

• Updating on the translational research activities and biomarker identification for patient selection in the ongoing phase I clinical study of FORX-428

Speakers:

Irena Konstantinova

Head of Biology

FoRx Therapeutics AG